com 134 135 Annual Report and Accounts for the year ended 30 June 2012 Stock Code: DPH Our Business Our Accounts Notes to the Company Financial Statements Reconciliation of Movements in Shareholders Funds For the year ended 30 June 2012 i Principal Accounting Policies of the Company 2012 2011 Accounting Principles 000 000 The Company Balance Sheet has been prepared under the historical cost convention except for derivatives which are stated at At start of year 72,382 73,045 fair value in accordance with applicable UK accounting standards and the Companies Act 2006.
Profit for the financial year 4,293 5,132 Effective portion of changes in fair value of cash flow hedges 335 506 Basis of Preparation Cash flow hedges recycled to profit and loss account 343 488 No profit and loss account is presented for the Company as permitted by Section 408 2 and 3 of the Companies Act 2006.
Share-based payments charge 1,001 903 The profit dealt with in the accounts of the Company was 4,293,000 2011: 5,132,000.
Fees paid to KPMG Audit Plc and Dividends paid 8,325 7,221 its associates for audit and non-audit services to the Company itself are not disclosed in the individual Financial Statements of New shares issued 59,288 541 Dechra Pharmaceuticals PLC because the Group Financial Statements are required to disclose such fees on a consolidated At end of year 128,647 72,382 basis.
Investments Investments held as fixed assets are stated at cost less any impairment losses.
Where the consideration for the acquisition of a subsidiary undertaking includes shares in the Company to which the provisions of section 612 of the Companies Act 2006 apply, cost represents the nominal value of the shares issued together with the fair value of any additional consideration given and costs.
Where investments are denominated in foreign currencies they are treated as monetary assets and revalued at each balance sheet date.
Intangible Assets Product rights that are acquired by the Company are stated at cost less accumulated amortisation and impairment losses.
Product rights are amortised over the period of their useful lives.
Derivative Financial Instruments The Company uses derivative financial instruments to manage its exposure to foreign exchange and interest rate risks.
In accordance with its treasury policy, the Company does not hold or issue derivative financial instruments for speculative purposes.
However, derivatives that do not qualify for hedge accounting are accounted for as trading instruments.
Derivative financial instruments are recognised initially at fair value.
Subsequent to initial recognition, derivative financial instruments are stated at fair value.
The gain or loss on remeasurement to fair value of instruments that do not qualify for hedge accounting is recognised immediately in the profit and loss account.
The fair value of interest rate swaps is the estimated amount that the Group would receive or pay to terminate the instrument at the balance sheet date.
The fair value of forward exchange contracts and options is their quoted market price at the balance sheet date, being the present value of the quoted forward price.
Hedging Cash Flow Hedges Changes in the fair value of derivative financial instruments designated as cash flow hedges are recognised directly in equity to the extent that the hedge is effective.
To the extent that the hedge is ineffective, changes in fair value are recognised as profit or loss.
If the hedging instrument no longer meets the criteria for hedge accounting, expires or is sold, terminated or exercised, then hedge accounting is discontinued prospectively.
The cumulative gain or loss previously recognised in equity remains there until the forecast transaction occurs.
When the hedged item is a non-financial asset, the amount recognised in equity is transferred to the carrying amount of the asset when it is recognised.
In other cases, the amount recognised in equity is transferred to profit or loss in the same period that the hedged item affects profit or loss.
Cash Flow Statement As the ultimate holding company of the Group, the Company has relied upon the exemption in FRS 1 Revised not to present a cash flow statement as part of its financial statements.
21587-04 10 08 2012 Proof 3 21587-04 10 08 2012 Proof 3 Shareholder Directors Report Directors Report Information Our Accounts Our Governance Our Performance Our Business Dechra Pharmaceuticals PLC www.
com 136 137 Annual Report and Accounts for the year ended 30 June 2012 Stock Code: DPH Our Business Our Accounts Notes to the Company Financial Statements continued i Principal Accounting Policies of the Company continued i Principal Accounting Policies of the Company continued Dividends Foreign Currency Dividends are recognised in the period in which they are approved by the Companys Shareholders or, in the case of an interim Foreign currency transactions are translated into Sterling using the exchange rates prevailing at the dates of the transactions.
dividend, when the dividend is paid.
Dividends receivable from subsidiaries are recognised when either received in cash or Monetary assets and liabilities are translated at the closing rate at the reporting date.
Foreign exchange gains and losses are applied to reduce a creditor balance with the subsidiary.
recognised in the profit and loss account.
Interest-bearing Borrowings Taxation Interest-bearing borrowings are recognised initially at fair value less attributable transaction costs.
Subsequent to initial The charge for taxation is based on the profit for the year and takes into account taxation deferred because of timing recognition, interest-bearing borrowings are stated at amortised cost with any difference between cost and redemption value differences between the treatment of certain items for taxation and accounting purposes.
Deferred tax is measured on a nonbeing recognised in the income statement over the period of the borrowings on an effective interest basis.
discounted basis at the tax rates that are expected to apply and have been substantively enacted in the periods in which the timing differences reverse and is provided in respect of all timing differences which have arisen but not reversed by the balance Related Parties sheet date, except as otherwise required by FRS 19 Deferred Tax.
Under FRS 8 the Company is exempt from the requirement to disclose related party transactions with other Group undertakings as they are all wholly owned within the Group and are included in the Dechra Pharmaceuticals PLC Consolidated Financial Guarantee Contracts Financial Statements.
Where the Company enters into financial guarantee contracts to guarantee the indebtedness of other companies within its Group, the Company considers these to be insurance arrangements, and accounts for them as such.
In this respect, the Company treats Transactions with Key Management Personnel the guarantee contract as a contingent liability until such time as it becomes probable that the Company will be required to make There were no material transactions with key management personnel except for those relating to remuneration see notes 7 a payment under the guarantee.
and 29 to the Consolidated Financial Statements and shareholdings.
ii Directors and Employees Transactions with Other Related Parties Total emoluments of Directors including pension contributions amounted to 1,727,000 2011: 1,696,000.
Information There are no controlling Shareholders of the Company.
There have been no material transactions with the Shareholders of the relating to Directors emoluments, share options and pension entitlements is set out in the Directors Remuneration Report on Company.
Employee Benefits iii Fixed Asset Investments i Pensions Shares in The Company operates a Group stakeholder personal pension scheme for certain employees.
Obligations for Subsidiary contributions are recognised as an expense in the profit and loss account as incurred.
Undertakings 000 ii Share-based Payment Transactions Cost The Company operates a number of equity settled share-based payment programmes that allow employees to acquire At 1 July 2011 132,119 shares of the Company.
The Company also operates a Long Term Incentive Plan for Directors and senior executives.
Additions 118,985 At 30 June 2012 251,104 The fair value of shares or options granted is recognised as an employee expense on a straight-line basis in the profit and Net book value loss account with a corresponding movement in equity.
The fair value is measured at grant date and spread over the period At 30 June 2012 251,104 during which the employees become unconditionally entitled to the shares or options the vesting period.
The fair value At 30 June 2011 132,119 of the shares or options granted is measured using a valuation model, taking into account the terms and conditions upon which the shares or options were granted.
The amount recognised as an expense in the profit and loss account is adjusted A list of principal subsidiary undertakings is given in note xi.
to take into account an estimate of the number of shares or options that are expected to vest together with an adjustment to reflect the number of shares or options that actually do vest except where forfeiture is only due to market-based conditions Additions represent the acquisition of Eurovet Animal Health B. V. and a further investment in Dechra Investments Limited a not being achieved.
The fair values of grants under the Long Term Incentive Plan have been determined using the Monte Carlo simulation Where subsidiaries are acquired for shares, or a combination of shares and cash, statutory merger relief has been applied and model.
The fair values of options granted under all other share option schemes have been determined using the Blackaccordingly cost includes the nominal value of shares issued.
National Insurance contributions payable by the Company on the intrinsic value of share-based payments at the date of exercise are treated as cash settled awards and revalued to market price at each balance sheet date.
Where the Company grants options over its own shares to the employees of its subsidiaries it recharges the expense to those subsidiaries.
com 138 139 Annual Report and Accounts for the year ended 30 June 2012 Stock Code: DPH Our Business Our Accounts Notes to the Company Financial Statements continued iv Intangible Assets vi Creditors Acquired Falling due Intangibles within one year 000 2012 2011 Cost 000 000 At 1 July 2011 Bank loans and overdrafts see note vii 4,411 31,564 Additions 5,114 Amounts due to subsidiary undertakings 28,557 9,930 At 30 June 2012 5,114 Other creditors 18 868 Amortisation Derivative financial instruments 387 397 At 1 July 2011 Other taxation and social security 79 Charge for the year 213 Accruals and deferred income 2,543 1,028 At 30 June 2012 213 35,916 43,866 Net book value At 30 June 2012 4,901 In accordance with FRS 21 Events after the Balance Sheet Date, the proposed final dividend for the year ended 30 June At 30 June 2011 2012 of 8.50p per share 2011: 7.72p per share restated to take into account the bonus element of the Rights Issue has not been accrued for in these financial statements.
It will be shown in the financial statements for the year ending 30 June 2013.
On 31 January 2012 the Company acquired the worldwide rights excluding Canada to HY-50, an equine lameness product.
The total cost of the proposed final dividend is 7,384,000 2011: 5,582,000.
The total consideration was 8.0 million Canadian Dollars 5.1 million which was paid in cash on completion.
Falling due after v Debtors more than one year 2012 2011 2012 2011 000 000 000 000 Amounts owed by subsidiary undertakings 18,735 36,836 Bank loans see note vii 113,800 55,746 Group relief receivable 1,699 2,248 113,800 55,746 Deferred taxation see note viii 571 639 Other debtors 301 98 Prepayments and accrued income 52 vii Borrowings 21,306 39,873 2012 2011 000 000 Borrowings due within one year Included in debtors are amounts of 571,000 2011: 639,000 due after more than one year relating to deferred tax assets.
Of Bank overdraft 23,564 the amounts owed by subsidiary undertakings, nil is due after more than one year 2011: 1,778,000.
Bank loan 5,000 8,000 Arrangement fees netted off 589 4,411 31,564 Borrowings due after more than one year Aggregate bank loan instalments repayable: between one and two years 10,000 8,000 between two and five years 105,757 47,746 after five years 115,757 55,746 Arrangement fees netted off 1,957 113,800 55,746 Total borrowings 118,211 87,310 The bank loans, revolving credit and overdraft facilities are secured by a fixed and floating charge on the assets of the Group.
Interest is charged at 2.5% over LIBOR on the bank loan and revolving credit facility and 2.5% over base rate on the bank overdraft.
No covenants have been breached during the year ended 30 June 2012.
The Company guarantees certain borrowings of other Group companies, which at 30 June 2012 amounted to 923,000 2011: 773,000.
com 140 141 Annual Report and Accounts for the year ended 30 June 2012 Stock Code: DPH Our Business Our Accounts Notes to the Company Financial Statements continued viii Deferred T ax xi Subsidiary Undertakings Dechra Pharmaceuticals PLC is the ultimate parent and controlling party of the Group.
000 At 1 July 2011 639 The principal subsidiary undertakings of the Company, all of which are wholly owned, are: Transfer to profit and loss 68 At 30 June 2012 included in debtors 571 Country of Company Incorporation Principal Activity The amounts provided for deferred taxation at 24% 2011: 26% are as follows: Operating Subsidiaries 2012 2011 Albrecht GmbH Germany Marketer of veterinary products and distributor of 000 000 veterinary products and equipment Short term timing differences 571 639 Dechra Limited England & Wales Developer, regulatory, manufacturer and marketer of veterinary products: wholesaler: provider of veterinary ix Called up Share Capital laboratory services Ordinary Shares Dechra Development LLC USA Regulatory and product development of 1p each Dechra Veterinary Products A S Denmark Manufacturer of veterinary products and marketer of Issued share capital 000 No.
veterinary products and pet diets Allotted, called up and fully paid at 1 July 2011 664 66,449,659 Dechra Veterinary Products OY# Finland Marketer of veterinary pharmaceuticals and pet diets Rights issue 2002000 201 20,040,653 Dechra Veterinary Products SAS# France Marketer of veterinary pharmaceuticals and pet diets New shares issued 4 379,864 Dechra Veterinary Products AS# Norway Marketer of veterinary pharmaceuticals and pet diets Allotted, called up and fully paid at 30 June 2012 869 86,870,176 Dechra Veterinary Products SLU# Spain Marketer of veterinary pharmaceuticals and pet diets Dechra Veterinary Products AB# Sweden Marketer of veterinary pharmaceuticals and pet diets Dechra Veterinary Products BV# The Netherlands Marketer of veterinary pharmaceuticals and pet diets Details of new ordinary shares issued following the Rights Issue, exercise of options under the Long Term Incentive Plan and the Approved, Unapproved and SAYE share option schemes are shown in note 23 to the consolidated financial statements.
Dechra Veterinary Products Limited# England & Wales Marketer of veterinary pharmaceuticals and pet diets Dechra Veterinary Products LLC USA Marketer of veterinary pharmaceuticals and pet diets Share Options Eurovet NV Belgium Marketer of veterinary pharmaceuticals and pet diets Details of outstanding share options over ordinary shares of 1p at 30 June 2012 under the various Group share option Eurovet Animal Health BV The Netherlands Manufacturer of veterinary products and marketer of schemes are shown in note 24 to the Consolidated Financial Statements.
veterinary products and pet diets Eurovet Animal Health Limited England & Wales Marketer of veterinary pharmaceuticals and pet diets x Reserves Scanimal Health ApS Denmark Marketer of veterinary pharmaceuticals and pet diets Share Profit Other Subsidiaries premium Hedging and loss Anglian Manufacturing Chemists Limited England & Wales Non-trading account reserve account Anglian Pharma Manufacturing Limited England & Wales Holding Company 000 000 000 Anglian Pharma Limited England & Wales Holding Company At 1 July 2011 63,559 294 8,453 Arnolds Veterinary Products Limited England & Wales Non-trading New shares issued 59,083 Cambridge Specialist Laboratory Services England & Wales Non-trading Profit for the financial year 4,293 Limited Effective portion of changes in fair value of cash flow hedges 335 Dales Pharmaceuticals Limited England & Wales Non-trading Cash flow hedges recycled to profit and loss account 343 Dechra Investments Limited England & Wales Holding Company Dividend see note 9 to the consolidated financial statements 8,325 Farvet Laboratories BV The Netherlands Non-trading Share-based payments charge 1,001 Genitrix Limited England & Wales In-liquidation At 30 June 2012 122,642 286 5,422 Leeds Veterinary Laboratories Limited England & Wales Non-trading National Veterinary Services Limited England & Wales Non-trading North Western Laboratories Limited England & Wales Holding Company Veneto Limited England & Wales Holding Company DermaPet, Inc. USA Non-trading 100% of ordinary share capital held by Veneto Limited.
Voting preference shares held by Dechra Pharmaceuticals PLC Employee Benefit Trust.
100% of ordinary share capital held by Dechra Investments Limited.
100% of ordinary share capital held by North Western Laboratories Limited.
100% of ordinary share capital held by Anglian Pharma Limited.
100% of ordinary share capital held by Anglian Pharma Manufacturing Limited.
# 100% of ordinary share capital held by Dechra Veterinary Products A S. 100% of ordinary share capital held by Dechra Veterinary Products LLC.
100% of ordinary share capital held by Dechra Limited.
100% of ordinary share capital held by Eurovet Animal Health B. V. 21587-04 10 08 2012 Proof 3 21587-04 10 08 2012 Proof 3 Shareholder Directors Report Directors Report Information Our Accounts Our Governance Our Performance Our Business Dechra Pharmaceuticals PLC www.
com 142 143 Annual Report and Accounts for the year ended 30 June 2012 Stock Code: DPH Our Business Our Accounts Financial History Glossary The following is a glossary of a number of the terms and MHRA 2012 2011 2010 2009 2008 acronyms which can be found within this document.
Medicines and Healthcare products Regulatory Agency: an 000 000 000 000 000 executive agency of the Department of Health.
Consolidated income statement Bioequivalence Revenue 426,041 389,237 369,369 349,964 304,371 The demonstration that the proposed formulation has the same NSAID Underlying operating profit 36,601 31,823 28,190 24,971 19,142 biological effects as the pioneer product to which it is being Non-Steroidal Anti-Inflammatory Drug: essentially drugs which Underlying profit before taxation 32,966 30,069 26,056 23,406 16,853 compared.
This is usually demonstrated by comparing blood relieve pain, swelling, stiffness and inflammation.
Equipalazone Underlying profit after taxation 24,302 22,748 19,437 16,759 12,185 concentrations of the active over time, but can be compared is the leading NSAID for the treatment of musculoskeletal Underlying earnings per share basic pence 32.37 31.53 27.09 23.52 19.11 using a clinical endpoint e. g. lowering of a worm count for disorders in the horse.
diluted pence 32.27 31.43 26.99 23.33 18.96 drugs that are not absorbed or for which blood levels cannot be Dividend per share pence 12.27 11.12 9.64 8.36 7.58 determined.
Otitis Externa Average number of employees 1,042 1,005 1,021 1,012 889 A condition which causes inflammation of the external ear canal Cortisol the tube between the outer ear and the ear drum.
Consolidated statement of financial position A hormone which is made by the adrenal glands.
Its production Non-current assets 242,592 132,819 88,044 97,605 99,652 is increased during episodes of stress and it has many effects Product Pipeline Working capital 49,531 32,494 21,486 17,548 17,284 on the body.
It helps regulate blood pressure, the immune This involves four stages which are as follows: Deferred and contingent consideration 13,863 14,055 system and helps balance the effect of insulin to keep the blood Current tax liabilities 8,155 5,391 4,105 4,756 2,824 sugar at normal levels.
Manufacturing the part of the dossier which documents Deferred tax liabilities 29,343 13,443 12,496 14,184 15,316 the quality, purity and physical characteristics of both the Employee benefit obligations 363 Cushings Syndrome active ingredient and the final formulation e. g. tablets, Net borrowings 86,717 34,091 6,701 15,527 26,997 A condition caused by excess cortisol see above and is named capsules, liquid.
Shareholders funds 153,682 98,333 86,228 80,686 71,799 after the physician who first described the condition in humans Safety the part of the dossier which documents the effects in the early twentieth century.
of the final formulation at above normal dosage levels in the Consolidated cash flow intended species.
Cash flow from operating activities 29,128 25,374 26,662 27,557 16,053 EBITDA Efficacy the part of the dossier which documents the Net interest paid 2,426 2,629 2,208 1,851 2,802 Earnings before interest, tax, depreciation and amortisation.
effectiveness of the final formulation in the intended species.
Tax paid 7,241 5,034 6,124 3,227 3,041 The studies may be controlled model studies or studies in Net capital expenditure 3,228 4,090 2,721 3,634 2,112 Euthyroid animals with the naturally occurring disease.
Acquisitions 117,335 33,047 65,151 Euthyroid is the state of having normal thyroid gland function.
Regulatory the period of time that regulatory agencies take Equity dividends paid 8,325 7,221 6,195 5,565 4,420 to review the various sections of the dossier.
Financing 112,033 26,090 4,626 8,843 66,500 FDA Changes in cash in period 2,606 557 4,788 4,437 5,027 US Food and Drug Administration: a federal agency of the US Staphylococcal Infections Restated to reflect the impact of the bonus element of the Rights Issue.
Department of Health and Human Services.
Communicable conditions caused by the Staphylococcus type of bacteria and generally characterised by pyoderma or the Hyperthyroidism formation of abscesses.
Occurs when the thyroid glands produce excessive amounts of thyroid hormone.
This causes an increase in the animals Surface Pyoderma metabolism the rate at which energy is burnt up.
Pyoderma is the medical term used to denote infections of the skin caused by bacteria.
Surface Pyoderma is a bacterial infection Intertrigo which is confined to the surface of the skin: one of the commonest Refers to a bacterial, fungal or viral infection that has developed types is known as Pyotraumatic Dermatitis acute moist dermatitis, at the site of broken skin due to inflammation of body folds.
It is typified by localised itching, moist reddened This infection is common in dogs with folds, such as Pugs or skin patches and ulcerated lesions.
Malassezia Yeasts that cause a secondary inflammatory skin disease.
Malassezia is often found in otitis externa.
21587-04 10 08 2012 Proof 3 21587-04 10 08 2012 Proof 3 Shareholder Directors Report Directors Report Information Our Accounts Our Governance Our Performance Our Business
